Cue Biopharma (CUE) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cue Biopharma (CUE) has outperformed Korro Bio (KRRO) over the past year, losing 30.0% versus a loss of 79.9%. Over five years, CUE leads with a -95.3% price change compared with -97.5% for KRRO. Korro Bio is the larger company by market cap ($125.0 million vs $121.4 million), about 1.0 times the size, while Cue Biopharma is growing revenue faster (+195.7% vs +181.5%).
Cue Biopharma converts more of its revenue into profit, with a net margin of -96.9% versus -1834.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | KRRO |
|---|---|---|
| Share price | $16.71 | $8.49 |
| Market cap | $121.39M | $125.02M |
| 1-day change | -10.50% | -8.81% |
| YTD return | +82.62% | +5.99% |
| 1-year return | -30.03% | -79.86% |
| 5-year return | -95.32% | -97.48% |
| EPS (TTM) | $-29.59 | $-9.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.47M | $6.39M |
| Revenue growth (YoY) | +195.75% | +181.46% |
| Net income (latest FY) | $-26.60M | $-117.26M |
| Operating margin | -96.67% | -1906.37% |
| Net margin | -96.85% | -1834.48% |
| 52-week high | $45.50 | $48.70 |
| 52-week low | $4.98 | $5.20 |
| Distance from 52-week high | -63.27% | -82.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +426.63% | +137.93% |
| Average volume | 272.41K | 151.92K |
| Shares outstanding | 7.26M | 14.73M |
| Employees | 29 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed KRRO by 49.8 percentage points over the past year.
- Cue Biopharma is more profitable, keeping -96.9 cents of every revenue dollar as net income versus -1834.5 cents for Korro Bio.
- Cue Biopharma grew revenue faster in its latest fiscal year (+195.75% vs +181.46%).
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
CUE vs KRRO FAQ
Which is bigger, Cue Biopharma or Korro Bio?
Korro Bio (KRRO) is larger, with a market capitalization of $125.02M compared with $121.39M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or KRRO?
CUE returned -30.03% over the past 12 months, compared with -79.86% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Korro Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.